AstraZeneca stock price forecast: traders eye consolidation as AZN faces near-term pressure

Traders Union
All News
Financial News
AstraZeneca slides 0.45% to GBX 13,658

Highlights

AstraZeneca's Enhertu received Breakthrough Therapy Designation in the US for HER2-positive early breast cancer, strengthening its oncology pipeline.
AstraZeneca extended a 10-year supply agreement with Niowave for Actinium-225 to support targeted radiopharmaceutical cancer therapies, enhancing long-term production capabilities.
The Phase III LATIFY trial of Imfinzi-ceralasertib in advanced lung cancer failed to meet its primary survival endpoint, with detailed results pending at an upcoming meeting.

Oncology progress and mixed trial data reshape sentiment

AstraZeneca advanced in oncology with its drug Enhertu receiving Breakthrough Therapy Designation in the US for HER2-positive early breast cancer. The company also extended a 10-year supply agreement for Actinium-225 with Niowave to support targeted radiopharmaceutical cancer therapies and launched new AI-powered cancer screening initiatives in the Philippines, highlighted at ESMO Asia 2025. Additionally, the Imfinzi-ceralasertib Phase III LATIFY trial in advanced lung cancer did not meet its main survival endpoint, and those results are set for presentation at an upcoming meeting.

Bullish momentum persists as short-term exhaustion signals emerge

Momentum remains supportive, as both MACD and ADX on daily and weekly charts signal sustained buying interest, and the stock structure confirms robust upward momentum. The RSI is mildly overbought but not extreme, with Stochastic RSI and Bull/Bear Power indicating buyers’ dominance, though CCI and the Awesome Oscillator remain neutral and suggest some hesitation. The price opened near the previous close and is now trading near the lower end of today's range after slipping 0.45% intraday, with moderate volatility and mild downward pressure following the open. Overall, momentum signals continue to emphasize bullishness, while short-term oscillators warn of exhaustion and hint at possible divergence.

Upward potential dominates as volatility bands constrain moves

Over the next five sessions, AstraZeneca is expected to trade within a typical volatility band between GBX 13,500 and GBX 14,000. There is a high probability, exceeding 80%, of an upward move as weekly and daily indicators favor buyers, with downside risk appearing limited. The base expectation is for sideways movement within this corridor as momentum normalizes. Should the price break above GBX 14,000, additional buying could quickly accelerate, while a drop below GBX 13,500 would likely trigger heavier profit-taking.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca maintaining technical strength above key longer-term averages but facing short-term hesitation near MA-20. He notes mixed sentiment after recent oncology advances and AI initiatives, offset by a negative trial update. Kharitonov believes momentum favors buyers, yet overbought oscillators and today’s price action reflect limited immediate upside. "Base case is sideways trade between GBX 13,500 and GBX 14,000 — I stay cautious unless we see a decisive break above resistance."

Last time, analysts noted that AstraZeneca PLC is maintaining a bullish structure with the price holding above its key short- and long-term moving averages while momentum indicators, including the MACD, support continued buyer strength despite some short-term mixed signals from oscillators. Resistance remains near the Ichimoku Kijun line and initial upside targets, with a high probability of further gains should bullish momentum persist, though price consolidation within a defined range is likely in the near term.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.